Uni-Bio Science Group Limited, a Hong Kong listed and headquartered company whose operations are largely in mainland China, will soon begin enrolling diabetes patients in its Phase III clinical trial for Recombinant Exendin-4 (rExendin-4 also known as exenatide). rExendin-4 is an incretin mimetic. Similar to the human incretin hormone glucagon-like peptide-1 (GLP-1), rExendin kicks in when blood sugar levels are high, such as following meals, to bring blood glucose levels back to normal levels. More details...

Stock Symbol: (HKEX: 0690)